Also trades as SNY, SNW.DE.
SAN.PA
Strong BuyFull HouseSanofi · Healthcare · France · $99.7B
EUR 69.99 -1.2% · close 5 Oct · scored 7 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Read our full research report on SAN.PA (Jun 2026), freeDoes StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT SANOFI
Read
Sanofi is a global pharmaceutical company focused on human health, developing and manufacturing a broad portfolio of innovative medicines, vaccines, and consumer healthcare products. The company holds strong market positions in key therapeutic areas such as vaccines, rare diseases, and immunology, underpinned by a deep R&D pipeline. Its global reach and diversified product offering provide resilience in a highly competitive industry.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.6B | 41.6B | 44.3B | 46.7B | 4.8% | 49.2B | 51.0B | 54.2B | 7.7% |
| EPS (EUR) | 5.37 | 4.31 | 4.59 | 6.40 | 6.0% | 3.25 | 7.02 | 7.43 | 7.7% |
| Shares | 1.3B | 1.3B | 1.3B | 1.2B | -4.2% | 1.2B | — | — | — |
| Debt | 21.2B | 18.4B | 17.9B | 20.3B | -1.4% | 23.7B | — | — | — |
| Equity | 74.8B | 74.0B | 77.5B | 71.4B | -1.5% | — | — | — | — |
| Op CF | 10.5B | 10.3B | 9.1B | 10.8B | 0.7% | 11.9B | — | — | — |
| Inv CF | -2.1B | -6.2B | -4.4B | -2.4B | — | — | — | — | — |
| Fin CF | -5.8B | -8.1B | -5.8B | -8.2B | — | — | — | — | — |
Calmer than 87% of stocks we rank over the past year (22% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SAN.PA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SAN.PA | Sanofi(you) | $99.7B | 89 | Strong Buy |
| GSK | GSK plc | $99.6B | 89 | Strong Buy |
| PFE | Pfizer Inc. | $160.6B | 89 | Strong Buy |
| N1VO34.SA | Novo Nordisk A/S | $169.4B | 89 | Strong Buy |
| BMY | Bristol-Myers Squibb Company | $124.9B | 98 | Strong Buy |
| AMGN | Amgen Inc. | $219.5B | 90 | Strong Buy |
| 4578.T | Otsuka Holdings Co., Ltd. | $36.6B | 91 | Strong Buy |
| NVS | Novartis AG | $271.3B | 87 | Strong Buy |
| GILD | Gilead Sciences, Inc. | $187.7B | 77 | Buy |
| ROP.SW | Roche Holding AG | $351.1B | 88 | Strong Buy |
Peer medians: ROE 2.5% · P/E 23.6x · Gross margin 53.4%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.